The Efficacy and Safety of Radiotherapy Plus Niraparib and Toripalimab in Patients With Recurrent Small Cell Lung Cancer

NCT05162196 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

57

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Small Cell Lung Cancer

Interventions

RADIATION: SBRT
DRUG: Toripalimab
DRUG: Niraparib

Sponsor

Wuhan University